Akero Therapeutics Inc [NASDAQ: AKRO] jumped around 9.43 points on Tuesday, while shares priced at $47.57 at the close of the session, up 24.72%.
Compared to the average trading volume of 1.14M shares, AKRO reached a trading volume of 6807880 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Akero Therapeutics Inc [AKRO]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AKRO shares is $73.83 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AKRO stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BofA Securities have made an estimate for Akero Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 30, 2025. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price from $50 to $72. The new note on the price target was released on January 27, 2025, representing the official price target for Akero Therapeutics Inc stock. Previously, the target price had yet another raise to $65, while Citigroup analysts kept a Buy rating on AKRO stock.
The Average True Range (ATR) for Akero Therapeutics Inc is set at 3.09 The Price to Book ratio for the last quarter was 3.50, with the Price to Cash per share for the same quarter was set at 8.61.
How has AKRO stock performed recently?
Akero Therapeutics Inc [AKRO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 18.90. With this latest performance, AKRO shares gained by 26.28% in over the last four-week period, additionally plugging by 59.85% over the last 6 months – not to mention a rise of 129.47% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AKRO stock in for the last two-week period is set at 62.88, with the RSI for the last a single of trading hit 67.59, and the three-weeks RSI is set at 59.64 for Akero Therapeutics Inc [AKRO]. The present Moving Average for the last 50 days of trading for this stock 41.25, while it was recorded at 40.48 for the last single week of trading, and 34.80 for the last 200 days.
Akero Therapeutics Inc [AKRO]: Deeper insight into the fundamentals
Akero Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 16.80 and a Current Ratio set at 16.80.
Earnings analysis for Akero Therapeutics Inc [AKRO]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AKRO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Akero Therapeutics Inc go to -8.83%.
Insider trade positions for Akero Therapeutics Inc [AKRO]
The top three institutional holders of AKRO stocks are: JANUS HENDERSON GROUP PLC with ownership of 6.88 million shares, which is approximately 9.9425%. BLACKROCK INC., holding 5.59 million shares of the stock with an approximate value of $$131.06 million in AKRO stocks shares; and BLACKROCK INC., currently with $$127.43 million in AKRO stock with ownership which is approximately 7.8542%.
